HMGB1 and Venous thrombosis: Such studies reported the use of deoxyribonuclease I (DNaseI) to inhibit venous thrombosis by pharmacologically disrupting NETs [163] and inhibiting receptors recognized by high mobility group protein-1 (HMGB1), including RAGE, TLR2, TLR4, and other receptors to inhibit venous thrombosis [164].